Context: Opioid-induced constipation is a common problem associated with chronic use of opioid analgesics.
Objectives: The objective of this study was to compare available interventions for the treatment of opioid-induced constipation, using principles of network meta-analysis.
Methods: Electronic databases were searched for randomized controlled clinical trials evaluating drugs used in opioid-induced constipation. Number of patients with rescue-free bowel movements (RFBM) was the primary outcome, and time for achieving RFBM, adverse events, and changes in the analgesic activity of the opioid analgesics were the secondary outcomes. Inverse variance heterogeneity model was used for direct and mixed treatment comparison analysis. Odds ratio for categorical outcomes and weighted mean difference for numerical outcomes were the effect estimates.
Results: We included a total of 23 studies in the systematic review and 21 in the network meta-analysis. Lubriprostone, prucalopride, naldemedine, naloxegol, alvimopan, subcutaneous, and oral methyl naltrexone were observed to perform better than placebo in terms of RFBM. Additionally, subcutaneous methyl naltrexone was significantly better than lubiprostone, naloxegol, oral methyl naltrexone, and prucalopride. Lubiprostone and naldemedine were associated with increased risks of adverse events. Subcutaneous methyl naltrexone did not significantly affect the analgesia due to background opioid use. Quality of evidence for the comparisons is either low or very low.
Conclusion: Subcutaneous methyl naltrexone was found to perform better than other interventions for managing opioid-induced constipation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2017.08.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of prophylactic laxatives against opioid-induced constipation: retrospective propensity score matching analysis.
Support Care Cancer
January 2025
Department of Anesthesiology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama-Shi, 641-8509, Japan.
Purpose: Opioid-induced constipation (OIC) is problematic for patients with cancer receiving opioid therapy. Some guidelines recommend initiating regular laxatives at the same time as opioid analgesics. However, the effectiveness of prophylactic laxatives on OIC has not been widely demonstrated.
View Article and Find Full Text PDFThe Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta-Analysis.
JGH Open
January 2025
Department of Nursing Hamad Medical Corporation Doha Qatar.
Background And Aim: Lubiprostone increases chloride and water secretion in the intestines, and several studies have demonstrated the efficacy of lubiprostone in treating functional constipation. Several new clinical trials have emerged since the previous meta-analysis conducted in 2020. We conducted this updated meta-analysis to assess clinical efficacy of lubiprostone in these patients.
View Article and Find Full Text PDFNavigating the Complexities of Anterior Cord Syndrome in a 71-Year-Old: A Case Study of Vertebral Osteomyelitis and Methicillin-Resistant Staphylococcus aureus Bacteremia.
Cureus
December 2024
Internal Medicine, Merit Health Wesley, Hattiesburg, USA.
Anterior cord syndrome is a rare yet critical neurological condition that poses significant challenges in clinical management. We present the case of a 71-year-old male with a medical history of hypertension, uncontrolled type II diabetes mellitus, hypothyroidism, and end-stage renal disease requiring dialysis who presented to the emergency department with complaints of chills, back pain, abdominal pain, and vomiting episodes. Based on the severity of the patient's illness, it was decided that inpatient admission would be best.
View Article and Find Full Text PDFEffects of a Revision to the Standard Admission Order Set on Laxative Prescribing for Opioid-Induced Constipation.
J Adv Pract Oncol
November 2024
From Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: Opioid-induced constipation (OIC) is highly prevalent in patients with cancer-related pain on opioid analgesics and has negative consequences on physical and psychological well-being and quality of life. Oncology clinical practice guidelines recommend the use of osmotic and stimulant laxatives for the prevention and management of opioid-induced constipation, not stool softeners such as docusate sodium. Prescribing practices continue to fall behind these recommendations.
View Article and Find Full Text PDFLactulose Versus Naloxone for Opioid-Induced Constipation in Intensive Care.
Turk J Pharm Sci
January 2025
Shahid Beheshti University of Medical Sciences Faculty of Medicine, Toxicological Research Center, Excellence Center and Department of Clinical Toxicology, Tehran, Iran.
Objectives: Constipation caused by opioid-induced constipation (OIC) is prevalent among critically poisoned patients and can result in complications that prolong hospitalization and, in rare cases, cause bowel perforatio This research aimed to evaluate the safety and efficacy of lactulose and naloxone in the treatment of OIC in the intensive care unit for poisoning.
Materials And Methods: This was a randomized, double-blind, clinical trial of patients with opioid poisoning who experienced constipation for 14 months. Patients were divided into two groups: one receiving lactulose (30 cc daily) and the other receiving naloxone (8 mg three times a day).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!